0001004724false00010047242026-11-112026-11-11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 11, 2026

Regional Health Properties, Inc.

(Exact Name of Registrant as Specified in its Charter)

Georgia

001-33135

81-5166048

(State or Other Jurisdiction

(Commission

(I.R.S. Employer

of Incorporation)

File Number)

Identification No.)

1050 Crown Pointe Parkway

Suite 720

Atlanta, Georgia 30338

(Address of Principal Executive Offices, and Zip Code)

(678) 869-5116

(Registrant’s telephone number, including area code)

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 11, 2026, the Board of Directors (the "Board") of Regional Health Properties, Inc. (the "Company"), acting pursuant to its authority under the Company's governing documents, appointed Robert M. Thornton, Jr. to fill the existing vacancy on the Board resulting from the resignation of C. Christian Winkle. Mr. Thornton's appointment was effective November 11, 2026. Following Mr. Thornton's appointment, the Board consists of seven directors. Mr. Thornton will serve until the Company's next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

 

As of the date of this report, the Board has not determined whether Mr. Thornton will serve on any committees of the Board.

 

Mr. Thornton, age 78, has served as the Company's Executive Vice President – Corporate Strategy since August 14, 2025, following the completion of the Company's merger with SunLink Health Systems, Inc. ("SunLink"). Prior to the merger, Mr. Thornton served as Chairman and Chief Executive Officer of SunLink since 1998 and as its President since July 1996. Mr. Thornton also served as SunLink's Chief Financial Officer from July 1997 through August 2002.

Mr. Thornton brings significant experience in healthcare operations, corporate strategy, acquisitions and capital allocation, which the Company believes will contribute to the Board's oversight of its integrated healthcare platform and long-term strategic initiatives.

There are no arrangements or understandings between Mr. Thornton and any other person pursuant to which he was selected as a director. Except as previously disclosed in the Company's filings with the Securities and Exchange Commission, there are no transactions involving Mr. Thornton requiring disclosure pursuant to Item 404(a) of Regulation S-K.

 

Mr. Thornton's existing employment agreement with the Company, entered into in connection with the SunLink merger on August 14, 2025, remains in effect. No additional compensation arrangements or equity awards were approved in connection with his appointment to the Board.

 

Item 8.01. Other Events.

Increase of Series B Preferred Stock Repurchase Program

On November 11, 2026, the Board approved an increase in the aggregate number of shares authorized for repurchase under the Company's previously announced stock repurchase program (the "Repurchase Program") for its 12.5% Series B Cumulative Redeemable Preferred Stock (the "Series B Preferred Stock").

 

The amendment increases the aggregate number of shares of Series B Preferred Stock authorized for repurchase under the Repurchase Program from 500,000 shares to 1,000,000 shares, representing an increase of 500,000 shares over the original authorization approved by the Board on November 25, 2025. The increased authorization includes shares previously repurchased pursuant to the Repurchase Program.

The Repurchase Program authorizes the Company to repurchase shares of its Series B Preferred Stock from time to time through open-market purchases, privately negotiated transactions, block trades or other transactions, including


pursuant to trading plans adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in each case subject to applicable securities laws.

The timing, number and price of shares repurchased will depend on market conditions, the trading price of the Series B Preferred Stock, available liquidity, regulatory requirements and other factors deemed relevant by the Company. The Special Committee of the Board will continue to oversee the timing, nature, amount and conduct of repurchases under the Repurchase Program.

The Repurchase Program does not obligate the Company to acquire any particular number of shares and may be modified, suspended or terminated at any time at the discretion of the Board. The Repurchase Program will continue until the authorized number of shares has been repurchased, unless earlier modified, suspended or terminated by the Board.

The Company expects to fund repurchases through available cash resources, subject to its liquidity needs and other capital allocation priorities.

The Board believes that the expanded Repurchase Program provides the Company with additional flexibility to manage its capital structure and pursue opportunities that may enhance long-term shareholder value.

 

 

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REGIONAL HEALTH PROPERTIES, INC.

Date:

November 19, 2026

By:

/s/ Brent Morrison

Brent Morrison

Chief Executive Officer and President